News Release

Non-Brokered Private Placement

Date: 2000/05/18

International Wex Technologies Inc. (the "company") announces the setting of a non-brokered private placement @2.47 per share with 2-year warrant attached. Numbers of shares: 500,000 common; price per share: $2.47; warrants : 500,000 shares exercisable @$2.90 during the first year and $3.48 per share during the second year expiring two years from the closing of the private placement. The proceeds of this private placement will be allocated towards the requirement and validation testing of Tetrodin for the IND filing with US FDA, Canadian HPB and EU EMEA and general working capital. The terms of this private placement is subject to approval by regulatory bodies.

Tetrodin(HT) has been developed by the company primarily as a treatment for the symptoms associated with withdrawal from all opiate addictions such as morphine, opium, heroin and methadone. It is a non-narcotic pharmaceutical that has proven to be safe and effective and functions well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction. The company has also begun tests on the usage of Tetrodin(HT) as a potent analgesic.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne , V. P. Shareholder Communications, at 604-683-8880 or 1-800-722-7549

Per: Donna Shum, Corporate Secretary